Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i> V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Baptiste Louveau(Inserm), Célèste Lebbé(Inserm), Aurélie Sadoux(Saint Louis University Hospital), Matthieu Resche‐Rigon(Inserm), Thierry Lesimple, Annick Tibi(Assistance Publique – Hôpitaux de Paris), Coralie Reger de Moura(Saint Louis University Hospital), Keyvan Rezaï(Hôpital René Huguenin), Didier Bouton(Assistance Publique – Hôpitaux de Paris), Mona Amini‐Adlé(Centre Léon Bérard), Zineb Ghrieb(Assistance Publique – Hôpitaux de Paris), Paul Vilquin(Université Claude Bernard Lyon 1), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Samuel Huguet(Institut Curie), Fanélie Jouenne(Inserm), Laetitia Da Meda(Assistance Publique – Hôpitaux de Paris), Julie Delyon(Inserm), Maxime Battistella(Peter MacCallum Cancer Centre), Samia Mourah(Assistance Publique – Hôpitaux de Paris), Barouyr Baroudjian, Marc Pracht(Canadian Partnership Against Cancer)
Cited by 19
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k